Copyright Reports & Markets. All rights reserved.

Global Anthracycline-based Anticancer Drugs API Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Anthracycline-based Anticancer Drugs API Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Epirubicin API
    • 1.3.3 Pirarubicin API
    • 1.3.4 Doxorubicin API
    • 1.3.5 Daunorubicin API
    • 1.3.6 Idarubicin API
    • 1.3.7 Others
  • 1.4 Market Analysis by Source
    • 1.4.1 Overview: Global Anthracycline-based Anticancer Drugs API Consumption Value by Source: 2021 Versus 2025 Versus 2032
    • 1.4.2 Natural Anthracycline APIs
    • 1.4.3 Semi-synthetic Anthracycline APIs
  • 1.5 Market Analysis by Purity
    • 1.5.1 Overview: Global Anthracycline-based Anticancer Drugs API Consumption Value by Purity: 2021 Versus 2025 Versus 2032
    • 1.5.2 Purity ≥99.5%
    • 1.5.3 Purity ≥99.0%
  • 1.6 Market Analysis by Application
    • 1.6.1 Overview: Global Anthracycline-based Anticancer Drugs API Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.6.2 Injectable Preparations
    • 1.6.3 Instillation Preparations
    • 1.6.4 Others
  • 1.7 Global Anthracycline-based Anticancer Drugs API Market Size & Forecast
    • 1.7.1 Global Anthracycline-based Anticancer Drugs API Consumption Value (2021 & 2025 & 2032)
    • 1.7.2 Global Anthracycline-based Anticancer Drugs API Sales Quantity (2021-2032)
    • 1.7.3 Global Anthracycline-based Anticancer Drugs API Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Pfizer
    • 2.1.1 Pfizer Details
    • 2.1.2 Pfizer Major Business
    • 2.1.3 Pfizer Anthracycline-based Anticancer Drugs API Product and Services
    • 2.1.4 Pfizer Anthracycline-based Anticancer Drugs API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Pfizer Recent Developments/Updates
  • 2.2 Synbias Pharma
    • 2.2.1 Synbias Pharma Details
    • 2.2.2 Synbias Pharma Major Business
    • 2.2.3 Synbias Pharma Anthracycline-based Anticancer Drugs API Product and Services
    • 2.2.4 Synbias Pharma Anthracycline-based Anticancer Drugs API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Synbias Pharma Recent Developments/Updates
  • 2.3 Intas Pharma
    • 2.3.1 Intas Pharma Details
    • 2.3.2 Intas Pharma Major Business
    • 2.3.3 Intas Pharma Anthracycline-based Anticancer Drugs API Product and Services
    • 2.3.4 Intas Pharma Anthracycline-based Anticancer Drugs API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Intas Pharma Recent Developments/Updates
  • 2.4 Microbiopharm Japan
    • 2.4.1 Microbiopharm Japan Details
    • 2.4.2 Microbiopharm Japan Major Business
    • 2.4.3 Microbiopharm Japan Anthracycline-based Anticancer Drugs API Product and Services
    • 2.4.4 Microbiopharm Japan Anthracycline-based Anticancer Drugs API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Microbiopharm Japan Recent Developments/Updates
  • 2.5 Teva
    • 2.5.1 Teva Details
    • 2.5.2 Teva Major Business
    • 2.5.3 Teva Anthracycline-based Anticancer Drugs API Product and Services
    • 2.5.4 Teva Anthracycline-based Anticancer Drugs API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Teva Recent Developments/Updates
  • 2.6 Humble Healthcaare
    • 2.6.1 Humble Healthcaare Details
    • 2.6.2 Humble Healthcaare Major Business
    • 2.6.3 Humble Healthcaare Anthracycline-based Anticancer Drugs API Product and Services
    • 2.6.4 Humble Healthcaare Anthracycline-based Anticancer Drugs API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Humble Healthcaare Recent Developments/Updates
  • 2.7 Olon S.p.A.
    • 2.7.1 Olon S.p.A. Details
    • 2.7.2 Olon S.p.A. Major Business
    • 2.7.3 Olon S.p.A. Anthracycline-based Anticancer Drugs API Product and Services
    • 2.7.4 Olon S.p.A. Anthracycline-based Anticancer Drugs API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Olon S.p.A. Recent Developments/Updates
  • 2.8 Hisun Pharma
    • 2.8.1 Hisun Pharma Details
    • 2.8.2 Hisun Pharma Major Business
    • 2.8.3 Hisun Pharma Anthracycline-based Anticancer Drugs API Product and Services
    • 2.8.4 Hisun Pharma Anthracycline-based Anticancer Drugs API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Hisun Pharma Recent Developments/Updates
  • 2.9 NCPC
    • 2.9.1 NCPC Details
    • 2.9.2 NCPC Major Business
    • 2.9.3 NCPC Anthracycline-based Anticancer Drugs API Product and Services
    • 2.9.4 NCPC Anthracycline-based Anticancer Drugs API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 NCPC Recent Developments/Updates
  • 2.10 Qilu Pharma
    • 2.10.1 Qilu Pharma Details
    • 2.10.2 Qilu Pharma Major Business
    • 2.10.3 Qilu Pharma Anthracycline-based Anticancer Drugs API Product and Services
    • 2.10.4 Qilu Pharma Anthracycline-based Anticancer Drugs API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Qilu Pharma Recent Developments/Updates
  • 2.11 DZD Pharma
    • 2.11.1 DZD Pharma Details
    • 2.11.2 DZD Pharma Major Business
    • 2.11.3 DZD Pharma Anthracycline-based Anticancer Drugs API Product and Services
    • 2.11.4 DZD Pharma Anthracycline-based Anticancer Drugs API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 DZD Pharma Recent Developments/Updates
  • 2.12 Sterling Biotech
    • 2.12.1 Sterling Biotech Details
    • 2.12.2 Sterling Biotech Major Business
    • 2.12.3 Sterling Biotech Anthracycline-based Anticancer Drugs API Product and Services
    • 2.12.4 Sterling Biotech Anthracycline-based Anticancer Drugs API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Sterling Biotech Recent Developments/Updates
  • 2.13 Flavine
    • 2.13.1 Flavine Details
    • 2.13.2 Flavine Major Business
    • 2.13.3 Flavine Anthracycline-based Anticancer Drugs API Product and Services
    • 2.13.4 Flavine Anthracycline-based Anticancer Drugs API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Flavine Recent Developments/Updates
  • 2.14 TTY Biopharm
    • 2.14.1 TTY Biopharm Details
    • 2.14.2 TTY Biopharm Major Business
    • 2.14.3 TTY Biopharm Anthracycline-based Anticancer Drugs API Product and Services
    • 2.14.4 TTY Biopharm Anthracycline-based Anticancer Drugs API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 TTY Biopharm Recent Developments/Updates

3 Competitive Environment: Anthracycline-based Anticancer Drugs API by Manufacturer

  • 3.1 Global Anthracycline-based Anticancer Drugs API Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Anthracycline-based Anticancer Drugs API Revenue by Manufacturer (2021-2026)
  • 3.3 Global Anthracycline-based Anticancer Drugs API Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Anthracycline-based Anticancer Drugs API by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Anthracycline-based Anticancer Drugs API Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Anthracycline-based Anticancer Drugs API Manufacturer Market Share in 2025
  • 3.5 Anthracycline-based Anticancer Drugs API Market: Overall Company Footprint Analysis
    • 3.5.1 Anthracycline-based Anticancer Drugs API Market: Region Footprint
    • 3.5.2 Anthracycline-based Anticancer Drugs API Market: Company Product Type Footprint
    • 3.5.3 Anthracycline-based Anticancer Drugs API Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Anthracycline-based Anticancer Drugs API Market Size by Region
    • 4.1.1 Global Anthracycline-based Anticancer Drugs API Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Anthracycline-based Anticancer Drugs API Consumption Value by Region (2021-2032)
    • 4.1.3 Global Anthracycline-based Anticancer Drugs API Average Price by Region (2021-2032)
  • 4.2 North America Anthracycline-based Anticancer Drugs API Consumption Value (2021-2032)
  • 4.3 Europe Anthracycline-based Anticancer Drugs API Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Anthracycline-based Anticancer Drugs API Consumption Value (2021-2032)
  • 4.5 South America Anthracycline-based Anticancer Drugs API Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Anthracycline-based Anticancer Drugs API Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Anthracycline-based Anticancer Drugs API Sales Quantity by Type (2021-2032)
  • 5.2 Global Anthracycline-based Anticancer Drugs API Consumption Value by Type (2021-2032)
  • 5.3 Global Anthracycline-based Anticancer Drugs API Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Anthracycline-based Anticancer Drugs API Sales Quantity by Application (2021-2032)
  • 6.2 Global Anthracycline-based Anticancer Drugs API Consumption Value by Application (2021-2032)
  • 6.3 Global Anthracycline-based Anticancer Drugs API Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Anthracycline-based Anticancer Drugs API Sales Quantity by Type (2021-2032)
  • 7.2 North America Anthracycline-based Anticancer Drugs API Sales Quantity by Application (2021-2032)
  • 7.3 North America Anthracycline-based Anticancer Drugs API Market Size by Country
    • 7.3.1 North America Anthracycline-based Anticancer Drugs API Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Anthracycline-based Anticancer Drugs API Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Anthracycline-based Anticancer Drugs API Sales Quantity by Type (2021-2032)
  • 8.2 Europe Anthracycline-based Anticancer Drugs API Sales Quantity by Application (2021-2032)
  • 8.3 Europe Anthracycline-based Anticancer Drugs API Market Size by Country
    • 8.3.1 Europe Anthracycline-based Anticancer Drugs API Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Anthracycline-based Anticancer Drugs API Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Anthracycline-based Anticancer Drugs API Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Anthracycline-based Anticancer Drugs API Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Anthracycline-based Anticancer Drugs API Market Size by Region
    • 9.3.1 Asia-Pacific Anthracycline-based Anticancer Drugs API Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Anthracycline-based Anticancer Drugs API Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Anthracycline-based Anticancer Drugs API Sales Quantity by Type (2021-2032)
  • 10.2 South America Anthracycline-based Anticancer Drugs API Sales Quantity by Application (2021-2032)
  • 10.3 South America Anthracycline-based Anticancer Drugs API Market Size by Country
    • 10.3.1 South America Anthracycline-based Anticancer Drugs API Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Anthracycline-based Anticancer Drugs API Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Anthracycline-based Anticancer Drugs API Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Anthracycline-based Anticancer Drugs API Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Anthracycline-based Anticancer Drugs API Market Size by Country
    • 11.3.1 Middle East & Africa Anthracycline-based Anticancer Drugs API Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Anthracycline-based Anticancer Drugs API Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Anthracycline-based Anticancer Drugs API Market Drivers
  • 12.2 Anthracycline-based Anticancer Drugs API Market Restraints
  • 12.3 Anthracycline-based Anticancer Drugs API Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Anthracycline-based Anticancer Drugs API and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Anthracycline-based Anticancer Drugs API
  • 13.3 Anthracycline-based Anticancer Drugs API Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Anthracycline-based Anticancer Drugs API Typical Distributors
  • 14.3 Anthracycline-based Anticancer Drugs API Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Anthracycline-based Anticancer Drugs API market size was valued at US$ 46.30 million in 2025 and is forecast to a readjusted size of US$ 50.20 million by 2032 with a CAGR of 1.0% during review period.
    Anthracycline-based anticancer APIs are among the most important cytotoxic chemotherapeutic intermediates, widely used in the treatment of solid tumors and hematological malignancies. Structurally derived from natural anthracycline antibiotics, they are typically produced through microbial fermentation followed by semi-synthetic modification, with high technical barriers in synthesis, purification, and quality control.The API supply chain of anthracycline anticancer drugs starts with intermediates such as anthraquinone core and daunorubicin. Semi-synthesis and sterile refining are adopted in production, and products are graded by pharmaceutical purity and high-purity grade. In 2026, mainstream pharmaceutical-grade APIs are priced at 25,000–55,000 USD/kg, with epirubicin and pirarubicin as core products. Global capacity is dominated by Chinese manufacturers, mainly used for injectables and local instillation preparations.
    This report is a detailed and comprehensive analysis for global Anthracycline-based Anticancer Drugs API market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Anthracycline-based Anticancer Drugs API market size and forecasts, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/Kg), 2021-2032
    Global Anthracycline-based Anticancer Drugs API market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/Kg), 2021-2032
    Global Anthracycline-based Anticancer Drugs API market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/Kg), 2021-2032
    Global Anthracycline-based Anticancer Drugs API market shares of main players, shipments in revenue ($ Million), sales quantity (Tons), and ASP (US$/Kg), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Anthracycline-based Anticancer Drugs API
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Anthracycline-based Anticancer Drugs API market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, Synbias Pharma, Intas Pharma, Microbiopharm Japan, Teva, Humble Healthcaare, Olon S.p.A., Hisun Pharma, NCPC, Qilu Pharma, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Anthracycline-based Anticancer Drugs API market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Epirubicin API
    Pirarubicin API
    Doxorubicin API
    Daunorubicin API
    Idarubicin API
    Others
    Market segment by Source
    Natural Anthracycline APIs
    Semi-synthetic Anthracycline APIs
    Market segment by Purity
    Purity ≥99.5%
    Purity ≥99.0%
    Market segment by Application
    Injectable Preparations
    Instillation Preparations
    Others
    Major players covered
    Pfizer
    Synbias Pharma
    Intas Pharma
    Microbiopharm Japan
    Teva
    Humble Healthcaare
    Olon S.p.A.
    Hisun Pharma
    NCPC
    Qilu Pharma
    DZD Pharma
    Sterling Biotech
    Flavine
    TTY Biopharm
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Anthracycline-based Anticancer Drugs API product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Anthracycline-based Anticancer Drugs API, with price, sales quantity, revenue, and global market share of Anthracycline-based Anticancer Drugs API from 2021 to 2026.
    Chapter 3, the Anthracycline-based Anticancer Drugs API competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Anthracycline-based Anticancer Drugs API breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Anthracycline-based Anticancer Drugs API market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Anthracycline-based Anticancer Drugs API.
    Chapter 14 and 15, to describe Anthracycline-based Anticancer Drugs API sales channel, distributors, customers, research findings and conclusion.

    Buy now